Abstract
ObjectivesTo evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in RAPID-PsA (NCT01087788), an ongoing Phase 3 trial in patients with psoriatic arthritis (PsA).MethodsPatients were randomised 1:1:1...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have